Answers are grounded in this paper and cite their sources.
Summary: An emerging strategy to enhance the efficacy of immune checkpoint blockade in relapsed/refractory cancers is increasing immunogenic cell death via combination with cytotoxic therapies. Understanding the effects of cytotoxic and immunotherapeutic agents on immune cell populations will enable improved mechanism-based design of combination therapies to maximum efficacy and minimum toxicity. See related article by Zeidner et al., p. 616.
No takes yet. Share an insight, caveat, or question.
Wei et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: